Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway

Neuroscience Letters

Volumn 471, Issue 1, 2010, Pages 53-57

  Ishii, Daisuke ^a   Matsuzawa, Daisuke ^a   Kanahara, Nobuhisa ^a   Matsuda, Shingo ^a   Sutoh, Chihiro ^a   Ohtsuka, Hiroyuki ^a   Nakazawa, Ken ^a   Kohno, Mami ^a   Hashimoto, Kenji ^b   Iyo, Masaomi ^a   Shimizu, Eiji ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Dopaminergic system; NMDA; Schizophrenia; Sensorimotor gating

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DIZOCILPINE; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSOL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR INTEGRATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIZOCILPINE MALEATE; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERAZINES; QUINOLONES; SIGNAL TRANSDUCTION; STARTLE REACTION;

EID: 75749101464     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.01.010     Document Type: Article

References (31)

1. Bast T., Zhang W., Feldon J., and White I.M. Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol. Biochem. Behav. 67 (2000) 647-658
2. Braff D.L., Geyer M.A., Light G.A., Sprock J., Perry W., Cadenhead K.S., and Swerdlow N.R. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr. Res. 49 (2001) 171-178
3. Browning J.L., Patel T., Brandt P.C., Young K.A., Holcomb L.A., and Hicks P.B. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol. Psychiatry 57 (2005) 617-623
4. Bubeníková V., Votava M., Horácek J., Pálenícek T., and Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol. Biochem. Behav. 80 (2005) 591-596
5. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
6. Fujikawa M., Nagashima M., Inoue T., Yamada K., and Furukawa T. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol. Biochem. Behav. 53 (1996) 903-909
7. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.) 156 (2001) 117-154
8. Geyer M.A., Mcllwain K.L., and Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry 7 (2002) 1039-1053
9. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
10. Gogos A., Bogeski M., and van den Buuse M. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behav. Pharmacol. 19 (2008) 548-561
11. Hashimoto K., Okamura N., Shimizu E., and Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr. Med. Chem. CNS Agents 4 (2004) 147-154
12. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
13. Kanahara N., Shimizu E., Ohgake S., Fujita Y., Kohno M., Hashimoto T., Matsuzawa D., Shirayama Y., Hashimoto K., and Iyo M. Glycine and d-serine, but not d-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology 198 (2008) 363-374
14. Keck Jr. P.E., and McElroy S.L. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert. Opin. Invest. Drugs 12 (2003) 655-662
15. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., and Morita S. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274 (1995) 329-336
16. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., and Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
17. Lipina T., Labrie V., Weiner I., and Roder J. Modulators of the glycine site on NMDA receptors. d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179 (2005) 54-67
18. Nakai S., Hirose T., Mori T., Stark A., Araki H., and Kikuchi T. The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats. Int. J. Neurosci. 118 (2008) 39-57
19. Nordquist R.E., Risterucci C., Moreau J.L., von Kienlin M., Künnecke B., Maco M., Freichel C., Riemer C., and Spooren W. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 54 (2008) 405-416
20. Olney J.W., and Farber N. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13 (1995) 335-345
21. Schotte A., Janssen P.F., Megens A.A., and Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631 (1993) 191-202
22. Schwieler L., Linderholm K.R., Nilsson-Todd L.K., Erhardt S., and Engberg G. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci. 83 (2008) 170-175
23. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 (2002) 27-38
24. Seger R. Differential activation of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-tetradecanoylphorbol-13-acetate (TPA) and insulin. Evidence for involvement of a TPA-stimulated protein-tyrosine kinase. J. Biol. Chem. 270 (1995) 28325-28330
25. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J. 9 (1995) 726-735
26. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J. Clin. Psychiatry 62 (2001) 841-842
27. Swerdlow N.R., Braff D.L., Geyer M.A., and Koob G.F. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol. Psychiatry 21 (1986) 23-33
28. Swerdlow N.R., Braff D.L., Taaid N., and Geyer M.A. Assessing the validity of an animal model of deficient sensorymotor gating in schizophrenia patients. Arch. Gen. Psychiatry 51 (1994) 139-154
29. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorigating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 24 (1998) 285-301
30. Urban J.D., Vargas G.A., von Zastrow M., and Mailman R.B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32 (2007) 67-77
31. Yamada S., Harano M., Annoh N., Nakamura K., and Tanaka M. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol. Psychiatry 46 (1999) 832-838